1. Home
  2. ZYME vs NEOG Comparison

ZYME vs NEOG Comparison

Compare ZYME & NEOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • NEOG
  • Stock Information
  • Founded
  • ZYME 2003
  • NEOG 1981
  • Country
  • ZYME United States
  • NEOG United States
  • Employees
  • ZYME N/A
  • NEOG N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • NEOG Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • ZYME Health Care
  • NEOG Health Care
  • Exchange
  • ZYME Nasdaq
  • NEOG Nasdaq
  • Market Cap
  • ZYME 1.2B
  • NEOG 1.3B
  • IPO Year
  • ZYME 2017
  • NEOG 1989
  • Fundamental
  • Price
  • ZYME $18.04
  • NEOG $5.89
  • Analyst Decision
  • ZYME Strong Buy
  • NEOG Buy
  • Analyst Count
  • ZYME 8
  • NEOG 4
  • Target Price
  • ZYME $24.00
  • NEOG $8.83
  • AVG Volume (30 Days)
  • ZYME 668.9K
  • NEOG 6.9M
  • Earning Date
  • ZYME 11-06-2025
  • NEOG 10-09-2025
  • Dividend Yield
  • ZYME N/A
  • NEOG N/A
  • EPS Growth
  • ZYME N/A
  • NEOG N/A
  • EPS
  • ZYME N/A
  • NEOG N/A
  • Revenue
  • ZYME $122,867,000.00
  • NEOG $886,886,000.00
  • Revenue This Year
  • ZYME $107.76
  • NEOG N/A
  • Revenue Next Year
  • ZYME $2.35
  • NEOG $2.17
  • P/E Ratio
  • ZYME N/A
  • NEOG N/A
  • Revenue Growth
  • ZYME 95.94
  • NEOG N/A
  • 52 Week Low
  • ZYME $9.03
  • NEOG $3.87
  • 52 Week High
  • ZYME $19.50
  • NEOG $16.79
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 65.50
  • NEOG 51.99
  • Support Level
  • ZYME $18.21
  • NEOG $5.78
  • Resistance Level
  • ZYME $19.10
  • NEOG $6.07
  • Average True Range (ATR)
  • ZYME 0.69
  • NEOG 0.35
  • MACD
  • ZYME 0.02
  • NEOG -0.02
  • Stochastic Oscillator
  • ZYME 56.97
  • NEOG 20.68

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About NEOG Neogen Corporation

Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.

Share on Social Networks: